Seeking Alpha

Bristol-Myers seeks approval in Japan for Hepatitis C combo

  • Bristol-Myers Squibb (BMY) has filed for Japanese authorization of its daclatasvir and asunaprevir combination treatment for Hepatitis C.
  • The move comes after the combo cured 84.7% of 222 patients after 24 weeks in a Phase III trial.
  • In early 2014, Bristol wants to test the drugs in a combination with another medicine, BMS791325, over a 12-week period.
  • Bristol-Myers submission is the first one that doesn't include the standard treatments interferon and ribavirin, which are difficult to tolerate. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|